Retatrutide – 5mg
Retatrutide is a Triple–Hormone-Receptor Agonist.
Retatrutide is an investigational single molecule that activates the body’s receptors for three hormones – glucagon, glucose-dependent insulinotropic polypeptide (GIP), and glucagon-like peptide-1 (GLP-1), and is being studied for the treatment of obesity. Retatrutide is an acylated peptide suitable for weekly injection.
- Aids in Weight Reduction
- Improves Blood Sugar Levels
- Improves Blood Pressure
The initial dose of retatrutide is 0.5 mg, which is injected subcutaneously once weekly. The dose of the drug can be increased to 1 mg, 2 mg, or 4 mg after 4 weeks, depending on the patient’s response. The maximum dose is 12 mg per week.
The initial dose of retatrutide is important because it helps to minimize the risk of side effects. If the patient tolerates the initial dose well, the dose can be increased gradually. However, if the patient experiences any serious side effects, the dose of the drug should be reduced or discontinued.
The information provided above is not intended to substitute medical advice, diagnosis, or treatment. Should you have any questions regarding a medical condition, seek the advice of your physician or a qualified healthcare provider. In no case should medical advice be disregarded or delayed because of what you have read or seen. We bear no responsibility or liability for your use of any of our research compounds and products. Please note that they are being sold for research purposes ONLY. We do NOT condone any personal use.